The Cytolethal Distending Toxin Subunit CdtB of Helicobacter Induces a Th17-related and Antimicrobial Signature in Intestinal and Hepatic Cells in Vitro

Journal of Infectious Diseases

Volumn 213, Issue 12, 2016, Pages 1979-1989

  Péré Védrenne, Christelle ^a,b   Cardinaud, Bruno ^a,c   Varon, Christine ^a,b   Mocan, Iulia ^a,b   Buissonnière, Alice ^a,b   Izotte, Julien ^a,b   Mégraud, Francis ^a,b   Ménard, Armelle ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Bordeaux Institute of Oncology   (France)

^c Inst Mathematiques de Bordeaux   (France)

Author keywords

CDT; Helicobacter hepaticus; Helicobacter pullorum; Inflammation; Kallikrein KLK5 KLK7; Microarray

Indexed keywords

CYTOLETHAL DISTENDING TOXIN; CYTOLETHAL DISTENDING TOXIN SUBUNIT CDTB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ARTICLE; BACTERIAL STRAIN; CACO 2 CELL LINE; CCL20 GENE; CCL26 GENE; CELL NUCLEUS; CX3CL1 GENE; CXCL10 GENE; CXCL20 GENE; CXCL9 GENE; CYTOKINE RELEASE; CYTOKINE RESPONSE; EPITHELIUM CELL; GENE; GENE EXPRESSION; HELICOBACTER HEPATICUS; HELICOBACTER PULLORUM; HUMAN; HUMAN CELL; IL32 GENE; IL7R GENE; IN VITRO STUDY; INNATE IMMUNITY; INTESTINE CELL; KLK5 GENE; KLK7 GENE; LIVER CELL; MULTIGENE FAMILY; NONHUMAN; PI3 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SLPI GENE; TH17 CELL; UPREGULATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HELICOBACTER; HELICOBACTER INFECTION; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; MUTATION; PATHOGENICITY; TUMOR CELL LINE;

ANTI-INFECTIVE AGENTS; BACTERIAL TOXINS; CELL LINE, TUMOR; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HELICOBACTER; HELICOBACTER INFECTIONS; HEPATOCYTES; HUMANS; INTERLEUKIN-8; INTESTINES; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TH17 CELLS; VIRULENCE FACTORS;

EID: 84974605228     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw042     Document Type: Article

References (49)

1. Stanley J, Linton D, Burnens AP, et al. Helicobacter pullorum sp. nov. -genotype and phenotype of a new species isolated from poultry and from human patients with gastroenteritis. Microbiology 1994; 140:3441-9.
2. Steinbrueckner B, Haerter G, Pelz K, et al. Isolation of Helicobacter pullorum from patients with enteritis. Scand J Infect Dis 1997; 29:315-8.
3. Laharie D, Asencio C, Asselineau J, et al. Association between entero-hepatic Helicobacter species and Crohn's disease: A prospective cross-sectional study. Aliment Pharmacol Ther 2009; 30:283-93.
4. Bohr UR, Glasbrenner B, Primus A, Zagoura A, Wex T, Malfertheiner P. Identification of enterohepatic Helicobacter species in patients suffering from inflammatory bowel disease. J Clin Microbiol 2004; 42:2766-8.
5. Pellicano R, Menard A, Rizzetto M, Megraud F. Helicobacter species and liver diseases: Association or causation? Lancet Infect Dis 2008; 8:254-60.
6. Borges V, Santos A, Correia CB, et al. Helicobacter pullorum isolated from fresh chicken meat: Antibiotic resistance and genomic traits of an emerging foodborne pathogen. Appl Environ Microbiol 2015; 81:8155-63.
7. Fox JG, Dewhirst FE, Tully JG, et al. Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J Clin Microbiol 1994; 32:1238-45.
8. Fox JG, Li X, Yan L, et al. Chronic proliferative hepatitis in A/JCr mice associated with persistent Helicobacter hepaticus infection: A model of helicobacter-induced carcinogenesis. Infect Immun 1996; 64:1548-58.
9. Fox JG, Ge Z, Whary MT, Erdman SE, Horwitz BH. Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer. Mucosal Immunol 2011; 4:22-30.
10. Young VB, Knox KA, Schauer DB. Cytolethal distending toxin sequence and activity in the enterohepatic pathogen Helicobacter hepaticus. Infect Immun 2000; 68:184-91.
11. Chien CC, Taylor NS, Ge Z, Schauer DB, Young VB, Fox JG. Identification of cdtB homologues and cytolethal distending toxin activity in enterohepatic Helicobacter spp. J Med Microbiol 2000; 49:525-34.
12. Bartonickova L, Sterzenbach T, Nell S, et al. Hcp and VgrG1 are secreted components of the Helicobacter hepaticus type VI secretion system and VgrG1 increases the bacterial colitogenic potential. Cell Microbiol 2013; 15:992-1011.
13. Sterzenbach T, Lee SK, Brenneke B, et al. Inhibitory effect of enterohepatic Helicobacter hepaticus on innate immune responses of mouse intestinal epithelial cells. Infect Immun 2007; 75:2717-28.
14. Varon C, Duriez A, Lehours P, et al. Study of Helicobacter pullorum proinflammatory properties on human epithelial cells in vitro. Gut 2009; 58:629-35.
15. Kleine M, Worbs T, Schrem H, et al. Helicobacter hepaticus induces an inflammatory response in primary human hepatocytes. PLoS One 2014; 9:e99713.
16. Ward JM, Anver MR, Haines DC, Benveniste RE. Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am J Pathol 1994; 145:959-68.
17. Ward JM, Fox JG, Anver MR, et al. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst 1994; 86:1222-7.
18. Ge Z, Rogers AB, Feng Y, et al. Bacterial cytolethal distending toxin promotes the development of dysplasia in a model of microbially induced hepatocarcinogenesis. Cell Microbiol 2007; 9:2070-80.
19. Guerra L, Guidi R, Frisan T. Do bacterial genotoxins contribute to chronic inflammation, genomic instability and tumor progression? FEBS J 2011; 278:4577-88.
20. Belibasakis GN, Bostanci N. Inflammatory and bone remodeling responses to the cytolethal distending toxins. Cells 2014; 3:236-46.
21. Avenaud P, Castroviejo M, Claret S, Rosenbaum J, Megraud F, Menard A. Expression and activity of the cytolethal distending toxin of Helicobacter hepaticus. Biochem Biophys Res Commun 2004; 318:739-45.
22. Varon C, Mocan I, Mihi B, et al. Helicobacter pullorum cytolethal distending toxin targets vinculin and cortactin and triggers formation of lamellipodia in intestinal epithelial cells. J Infect Dis 2014; 209:588-99.
23. Young VB, Knox KA, Pratt JS, et al. In vitro and in vivo characterization of Helicobacter hepaticus cytolethal distending toxin mutants. Infect Immun 2004; 72:2521-7.
24. Le Roux-Goglin E, Dubus P, Asencio C, Jutand MA, Rosenbaum J, Megraud F. Hepatic lesions observed in hepatitis C virus transgenic mice infected by Helicobacter hepaticus. Helicobacter 2013; 18:33-40.
25. Akifusa S, Poole S, Lewthwaite J, Henderson B, Nair SP. Recombinant Actinobacillus actinomycetemcomitans cytolethal distending toxin proteins are required to interact to inhibit human cell cycle progression and to stimulate human leukocyte cytokine synthesis. Infect Immun 2001; 69:5925-30.
26. Blazkova H, Krejcikova K, Moudry P, Frisan T, Hodny Z, Bartek J. Bacterial intoxication evokes cellular senescence with persistent DNA damage and cytokine signalling. J Cell Mol Med 2010; 14:357-67.
27. Zheng J, Meng J, Zhao S, Singh R, Song W. Campylobacter-induced interleukin-8 secretion in polarized human intestinal epithelial cells requires Campylobactersecreted cytolethal distending toxin- and Toll-like receptor-mediated activation of NF-kappaB. Infect Immun 2008; 76:4498-508.
28. Jones MA, Totemeyer S, Maskell DJ, Bryant CE, Barrow PA. Induction of proinflammatory responses in the human monocytic cell line THP-1 by Campylobacter jejuni. Infect Immun 2003; 71:2626-33.
29. Hickey TE, McVeigh AL, Scott DA, et al. Campylobacter jejuni cytolethal distending toxin mediates release of interleukin-8 from intestinal epithelial cells. Infect Immun 2000; 68:6535-41.
30. Hynes SO, Ferris JA, Szponar B, et al. Comparative chemical and biological characterization of the lipopolysaccharides of gastric and enterohepatic helicobacters. Helicobacter 2004; 9:313-23.
31. Sakamoto K, Masuda T, Mita S, et al. Interleukin-8 is constitutively and commonly produced by various human carcinoma cell lines. Int J Clin Lab Res 1992; 22:216-9.
32. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity. J Immunol 2001; 167:623-7.
33. Hoover DM, Boulegue C, Yang D, et al. The structure of human macrophage inflammatory protein-3alpha /CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J Biol Chem 2002; 277:37647-54.
34. Kolls JK, McCray PB Jr., Chan YR. Cytokine-mediated regulation of antimicrobial proteins. Nat Rev Immunol 2008; 8:829-35.
35. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13:975-80.
36. Kullberg MC, Jankovic D, Feng CG, et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 2006; 203:2485-94.
37. Morrison PJ, Bending D, Fouser LA, et al. Th17-cell plasticity in Helicobacter hepaticus-induced intestinal inflammation. Mucosal Immunol 2013; 6:1143-56.
38. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 2003; 9:1710-20.
39. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72:1622-31.
40. Meijer B, Gearry RB, Day AS. The role of S100A12 as a systemic marker of inflammation. Int J Inflam 2012; 2012:907078.
41. Hattinger E, Zwicker S, Ruzicka T, Yuspa SH, Wolf R. Opposing functions of psoriasin (S100A7) and koebnerisin (S100A15) in epithelial carcinogenesis. Curr Opin Pharmacol 2013; 13:588-94.
42. Nasser MW, Qamri Z, Deol YS, et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012; 72:604-15.
43. Liu H, Wang L, Wang X, Cao Z, Yang Q, Zhang K. S100A7 enhances invasion of human breast cancer MDA-MB-468 cells through activation of nuclear factorkappaB signaling. World J Surg Oncol 2013; 11:93.
44. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res 2007; 27:3051-8.
45. Liu B, Sun WY, Zhi CY, et al. Role of S100A3 in human colorectal cancer and the anticancer effect of cantharidinate. Exp Ther Med 2013; 6:1499-503.
46. Kang M, Lee HS, Lee YJ, et al. S100A3 suppression inhibits in vitro and in vivo tumor growth and invasion of human castration-resistant prostate cancer cells. Urology 2015; 85:273. e9-15.
47. Wang X, Yang J, Qian J, Liu Z, Chen H, Cui Z. S100A14, a mediator of epithelialmesenchymal transition, regulates proliferation, migration and invasion of human cervical cancer cells. Am J Cancer Res 2015; 5:1484-95.
48. Kizawa K, Takahara H, Unno M, Heizmann CW. S100 and S100 fused-type protein families in epidermal maturation with special focus on S100A3 in mammalian hair cuticles. Biochimie 2011; 93:2038-47.
49. Donato R, Cannon BR, Sorci G, et al. Functions of S100 proteins. Curr Mol Med 2013; 13:24-57.